HoneyNaps announced on 9 September that it has commenced exports of its artificial intelligence sleep disorder diagnostic software, SOMNUM, to two medical institutions in the United States.

This marks the third approval of its kind from the U.S. Food and Drug Administration (FDA) in 2023.

SOMNUM is more than just a system for interpreting biometric signal images; it is a deep learning-based AI solution capable of real-time analysis of multi-channel, temporal, and large-scale biometric signals.

The software was developed using the world’s first explainable medical AI (XAI) technology.

The SOMNUM solution will be utilised in research focusing on sleep health for seniors and in verifying sleep improvement programmes. HoneyNaps has established a licensing agreement based on annual usage fees for the software.

Currently, HoneyNaps is enhancing its B2B operations with major companies in South Korea while also pursuing local sales through its subsidiary in Boston and dealer channels on the West Coast, anticipating continued growth in export volumes.

The U.S. market is recognised as the largest for sleep medicine globally and still presents significant growth potential. HoneyNaps aims to solidify its business strategy in the U.S. with a target of capturing 10% of the market share within the next three years.






Source: prnewswire.com

Report Abuse